# Murrayazolinine (Murraya koenigii)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/murrayazolinine-murraya-koenigii
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** carbazole alkaloid curry leaf, pyranocarbazole alkaloid, Murrayazolinine (from Murraya koenigii), Murraya koenigii leaf alkaloid, murrayazoline

## Overview

Murrayazolinine is a pyranocarbazole alkaloid that induces apoptosis in cancer cells by downregulating the Akt/mTOR survival signaling pathway, triggering G2/M cell cycle arrest, ROS elevation, [mitochondrial](/ingredients/condition/energy) membrane depolarization, and caspase-3 activation. In preclinical in vitro assays against DLD-1 human colon cancer cells, it demonstrated potent cytotoxicity with an IC50 of 5.7 μM while exhibiting no cytotoxicity in non-cancerous HEK-293 and HaCaT cell lines at equivalent concentrations.

## Health Benefits

- **Anticancer Activity (Colon Cancer)**: Murrayazolinine suppresses proliferation of DLD-1 colon cancer cells with an IC50 of 5.7 μM, selectively sparing non-cancer HEK-293 and HaCaT cells, suggesting a favorable therapeutic window in preclinical models.
- **Apoptosis Induction**: The compound activates the intrinsic apoptotic pathway by increasing the Bax/Bcl-2 ratio and activating caspase-3, leading to programmed cell death specifically in malignant cell populations.
- **Cell Cycle Arrest**: Murrayazolinine promotes G2/M phase arrest in cancer cells, halting cellular replication and preventing tumor cell division as demonstrated in DLD-1 cell line studies.
- **Oxidative Stress Modulation in Cancer Cells**: The compound elevates intracellular [reactive oxygen species](/ingredients/condition/antioxidant) (ROS) in cancer cells, contributing to [mitochondrial](/ingredients/condition/energy) membrane depolarization and subsequent apoptotic signaling.
- **Akt/mTOR Pathway Inhibition**: By downregulating the Akt/mTOR signaling axis, murrayazolinine disrupts a key pro-survival and pro-proliferative pathway frequently hyperactivated in colorectal and other solid-tumor cancers.
- **[Anti-inflammatory](/ingredients/condition/inflammation) Potential (Source Plant)**: As part of the broader alkaloid profile of Murraya koenigii leaves, murrayazolinine contributes to the plant's reported anti-inflammatory bioactivity, though specific molecular targets for this compound in inflammation have not been individually characterized.
- **[Neuroprotective](/ingredients/condition/cognitive) Context (Related Alkaloids)**: Closely related Murraya carbazole alkaloids—murrayanol and mahanimbine—inhibit acetylcholinesterase (AChE) with IC50 values of approximately 0.2 μg/mL and reduce amyloid-beta (Aβ) fibrillization, suggesting that the broader carbazole class from this botanical source may support neurological health, though this has not been confirmed for murrayazolinine specifically.

## Mechanism of Action

Murrayazolinine exerts its primary characterized activity through downregulation of the Akt/mTOR intracellular signaling pathway, a critical regulator of cell survival, growth, and proliferation that is frequently dysregulated in colorectal cancers. This pathway suppression leads to downstream consequences including G2/M cell cycle arrest, preventing cancer cells from completing mitosis. Concurrently, the compound elevates intracellular [reactive oxygen species](/ingredients/condition/antioxidant) (ROS), induces [mitochondrial](/ingredients/condition/energy) membrane depolarization, and shifts the balance of apoptosis-regulatory proteins toward cell death by increasing the Bax/Bcl-2 ratio and activating executioner caspase-3. The compound's selectivity for cancer versus non-cancer cells—evidenced by absence of cytotoxicity in HEK-293 and HaCaT lines—implies a mechanistic dependence on the aberrant signaling environment characteristic of transformed cells, though the precise receptor or binding-site interactions governing this selectivity have not yet been fully elucidated.

## Clinical Summary

No clinical trials investigating murrayazolinine as an isolated compound or as a standardized component of Murraya koenigii extract have been conducted or registered. All quantified efficacy data derive exclusively from in vitro cell-line experiments, providing no information on pharmacokinetics, effective human doses, tolerability, or comparative clinical outcomes. The IC50 of 5.7 μM in DLD-1 colon cancer cells represents a cellular potency metric only and cannot be extrapolated to human therapeutic doses without bioavailability, distribution, and safety data. Confidence in any clinical benefit is therefore very low, and murrayazolinine should be regarded strictly as a research-stage phytochemical compound with unproven clinical utility.

## Nutritional Profile

Murrayazolinine as an isolated alkaloid compound does not possess a conventional nutritional profile (macronutrients, vitamins, minerals). As a pyranocarbazole alkaloid, it is a nitrogen-containing secondary metabolite with a molecular structure comprising a carbazole tricyclic aromatic core fused with a pyran ring system. Its concentration in Murraya koenigii leaf material has not been quantified in available published literature. Whole Murraya koenigii leaves, from which it derives, contain dietary fiber, essential oils (sabinene, β-gurjunene), carbazole alkaloids (mahanimbine, murrayanol, murrayafoline A), flavonoids, and minerals (iron, calcium), but these nutritional components are not attributed to murrayazolinine specifically. Bioavailability of the alkaloid from whole-leaf consumption is predicted to be limited based on in silico ADMET modeling of structurally related carbazole compounds showing poor solubility and absorption.

## Dosage & Preparation

- **Research-Grade Isolated Compound**: Murrayazolinine is isolated from Murraya koenigii leaf material via organic solvent extraction (e.g., methanol or ethanol) followed by chromatographic purification; no commercial supplement form exists.
- **Traditional Leaf Consumption (Whole Plant)**: Fresh or dried curry leaves are consumed as a culinary spice in South and Southeast Asian cooking; typical culinary use involves 5–15 leaves per meal, but this is not a medicinal dose of isolated alkaloid.
- **Ayurvedic Decoction (Source Plant)**: Traditional Ayurvedic preparations use dried Murraya koenigii leaf powder (1–3 g) or decoctions (10–20 g dried leaf boiled in water), though alkaloid content in these preparations is unstandardized.
- **Standardized Supplement**: No commercially standardized extract specifying murrayazolinine content is available; no effective dose range from clinical trials can be cited.
- **Bioavailability Note**: In silico ADMET modeling of related Murraya carbazoles (e.g., murrayanol, mahanimbine) predicts poor aqueous solubility and limited oral absorption, suggesting that meaningful bioavailability of murrayazolinine from whole-leaf consumption may be low without formulation enhancement.

## Safety & Drug Interactions

Murrayazolinine has demonstrated no cytotoxicity against non-cancerous human cell lines (HEK-293 embryonic kidney cells and HaCaT keratinocytes) at concentrations effective against DLD-1 colon cancer cells in vitro, suggesting a preliminary favorable selectivity index. However, no human safety data exist—including no clinical adverse effect profiles, maximum tolerated dose, organ toxicity data, or pharmacovigilance reports—as the compound has not been studied in humans or in animal models. Drug interaction potential is entirely unstudied; theoretical concerns exist for co-administration with mTOR inhibitors (e.g., everolimus, sirolimus), chemotherapeutic agents, or anticoagulants given the bioactive alkaloid nature of the compound, but no empirical interaction data are available. Murraya koenigii leaves as a whole food are generally regarded as safe in traditional culinary use; however, isolated or concentrated murrayazolinine cannot be assumed safe based on leaf safety alone, and use in pregnancy, lactation, or pediatric populations cannot be evaluated without human data.

## Scientific Research

The entire evidence base for murrayazolinine consists of preclinical in vitro studies; no animal (in vivo) studies or human clinical trials have been published as of the available literature. The most robust data originate from cell-line experiments using DLD-1 human colon adenocarcinoma cells, where an IC50 of 5.7 μM was established alongside mechanistic assays confirming Akt/mTOR downregulation, caspase-3 activation, and ROS elevation. Comparative in vitro studies on structurally related Murraya koenigii carbazoles (murrayanol, mahanimbine, O-methylmurrayamine A) provide contextual mechanistic insight, including AChE inhibition and Aβ fibrillization data, but these findings cannot be directly attributed to murrayazolinine. Researchers in the field explicitly recommend controlled clinical trials to validate the anticancer and [neuroprotective](/ingredients/condition/cognitive) claims derived from these herbal alkaloids, underscoring the early-stage nature of the evidence.

## Historical & Cultural Context

Murraya koenigii leaves have been used in Indian Ayurvedic medicine for centuries, with documented applications in the management of hyperglycemia, inflammatory conditions, piles, leucoderma, blood disorders, and bronchial complaints. The tree holds cultural significance in Hindu religious rituals and is considered an auspicious plant in several South Asian traditions, often grown in domestic gardens for both culinary and spiritual purposes. Classical Ayurvedic texts reference the leaves as having tikta (bitter) and kashaya (astringent) rasas, properties associated with [anti-inflammatory](/ingredients/condition/inflammation) and detoxifying actions. The isolation and characterization of specific alkaloids such as murrayazolinine represents a modern phytochemical effort to identify the molecular basis of these traditional claims, though the compound itself was not known or named in historical herbal practice.

## Synergistic Combinations

No empirically validated synergistic combinations for murrayazolinine have been studied. Within the Murraya koenigii alkaloid complex, murrayazolinine co-occurs with mahanimbine and murrayanol, which inhibit [acetylcholine](/ingredients/condition/cognitive)sterase and reduce amyloid-beta fibrillization, suggesting that whole-leaf or multi-alkaloid extracts may provide broader bioactivity than any single isolated compound—a theoretical synergy consistent with the entourage concept in phytochemistry. In preclinical oncology contexts, compounds targeting the Akt/mTOR pathway (as murrayazolinine does) have shown additive or synergistic effects when combined with PI3K inhibitors or conventional chemotherapeutics such as 5-fluorouracil, though no such combinations have been tested with murrayazolinine specifically.

## Frequently Asked Questions

### What is murrayazolinine and where does it come from?

Murrayazolinine (also spelled murrayazoline) is a pyranocarbazole alkaloid—a nitrogen-containing secondary plant metabolite—isolated from the leaves of Murraya koenigii, commonly known as the curry leaf tree. The tree is native to the Indian subcontinent and Southeast Asia, where its leaves have been used in Ayurvedic medicine and South Asian cuisine for centuries. The compound itself is extracted for research purposes via organic solvent isolation and has not been developed into a commercial supplement.

### Does murrayazolinine have anticancer properties?

Preclinical in vitro evidence shows murrayazolinine inhibits human DLD-1 colon cancer cell proliferation with an IC50 of 5.7 μM by downregulating the Akt/mTOR cell survival pathway, inducing G2/M cell cycle arrest, elevating intracellular ROS, and activating caspase-3-mediated apoptosis. Importantly, it showed no cytotoxicity in non-cancerous HEK-293 and HaCaT cell lines at equivalent concentrations. However, no animal studies or human clinical trials have been conducted, so these findings cannot yet be translated into clinical cancer treatment recommendations.

### What is the mechanism of action of murrayazolinine?

Murrayazolinine primarily acts by suppressing the Akt/mTOR signaling pathway, a key regulator of cell survival and proliferation that is frequently overactivated in cancer cells. This leads to a cascade of pro-apoptotic events: G2/M cell cycle arrest, mitochondrial membrane depolarization, increased reactive oxygen species (ROS), a shift in the Bax/Bcl-2 apoptotic protein ratio toward cell death, and activation of the executioner enzyme caspase-3. The apparent selectivity for cancer over non-cancer cells suggests the mechanism exploits the aberrant signaling environment of transformed cells, though the precise binding targets have not been fully characterized.

### Is murrayazolinine safe to take as a supplement?

Murrayazolinine is not available as a standardized commercial supplement, and no human safety data—including toxicity thresholds, adverse effect profiles, or drug interaction studies—have been published. In vitro studies show no harm to non-cancerous human cell lines at effective concentrations, and in silico ADMET modeling of structurally related carbazoles suggests low toxicity potential, but these data cannot substitute for human clinical safety evaluation. Whole curry leaves (Murraya koenigii) are considered generally safe as a culinary ingredient, but concentrated or isolated alkaloid preparations carry unknown risks, particularly for pregnant or breastfeeding individuals.

### How does murrayazolinine compare to other Murraya koenigii alkaloids?

Among the characterized alkaloids from Murraya koenigii, murrayazolinine demonstrates the most potent anticancer activity in DLD-1 colon cancer cells (IC50 5.7 μM) compared to O-methylmurrayamine A (IC50 17.9 μM). Related alkaloids murrayanol and mahanimbine show distinct neuroprotective properties, inhibiting acetylcholinesterase with IC50 values of approximately 0.2 μg/mL—outperforming the reference drug galantamine—and reducing amyloid-beta fibrillization by 40.83% and 27.68% respectively. These compounds collectively suggest that Murraya koenigii leaf alkaloids are pharmacologically diverse, with each compound displaying partially distinct bioactivities and molecular targets.

### What does current clinical research show about murrayazolinine's effectiveness against cancer?

Most evidence for murrayazolinine comes from laboratory and preclinical studies, where it has demonstrated selective anticancer activity against colon cancer cells (DLD-1) with an IC50 of 5.7 μM while sparing healthy cells. However, human clinical trials are limited, meaning efficacy and safety in patients have not yet been established through gold-standard evidence. The compound shows promise as a research candidate, but supplementation cannot be recommended as a cancer treatment based on current data.

### Who should consider murrayazolinine supplementation, and who should avoid it?

Murrayazolinine may be of interest to individuals researching natural alkaloids with bioactive properties, particularly those studying traditional uses of curry leaf (Murraya koenigii). Pregnant women, nursing mothers, and individuals with existing cancer treatments should avoid murrayazolinine supplements without consulting a healthcare provider, as safety data in these populations is absent. People taking medications metabolized by the liver should also exercise caution, as alkaloid interactions have not been thoroughly characterized.

### How does murrayazolinine's apoptosis mechanism make it different from standard cancer cell research compounds?

Murrayazolinine activates apoptosis through the intrinsic pathway by increasing the Bax/Bcl-2 ratio and engaging caspase-3, a well-characterized mechanism that is distinct from many synthetic chemotherapy agents. What sets it apart in preclinical work is its apparent selectivity—it induces apoptosis in cancer cells while demonstrating minimal toxicity to non-cancer cell lines, suggesting a potentially favorable therapeutic window. This selective profile makes it noteworthy for basic research, though selective toxicity in human trials remains unproven.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*